The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia

Imre Kovács, Erzsébet Toldy, Tatjana Ábel, Jenö Tarján, A. Császár

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Impairment of flow-mediated dilation (FMD) has been shown to be associated with hypercholesterolemia and hypertriglyceridemia and reduction of cholesterol and/or triglyceride levels can improve FMD. In hyperlipidemia the role of inflammatory substances on endothelial function requires further clarification. In patients with combined hyperlipidemia (n=29), the capacity of FMD was weaker whereas the levels of interleukin (IL)-1α, tumor necrosis factor alpha (TNFα), soluble intercellular adhesion molecule (sICAM), and fibrinogen were higher compared to normolipemic controls with normal FMD adjusted for age and sex. Patients were randomized to a diet-only or to a ciprofibrate treatment group. After 8 weeks FMD levels rose significantly both in the diet-only (10.2%) and the ciprofibrate treatment (79.4%) groups. In the diet-only group improvement of FMD was significantly associated with the reduction of triglyceride (by 15.9%) and cholesterol (6.9%) levels. The much larger improvement of FMD due to ciprofibrate therapy was accompanied by significant reductions of cholesterol (by 14.4%), fibrinogen, IL-1α, and sICAM levels and by significant increase of high-density lipoprotein (HDL) cholesterol concentration, but the change in FMD correlated only with the reduction of the cholesterol level. In line with previous data the authors emphasize that improvement of FMD in patients with combined hyperlipidemia treated with diet and/or ciprofibrate is linked directly to the reduction of cholesterol and triglyceride concentrations rather than to changes in the level of the investigated inflammatory markers.

Original languageEnglish
Pages (from-to)179-183
Number of pages5
JournalEndothelium: Journal of Endothelial Cell Research
Volume12
Issue number4
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Hyperlipidemias
Dilatation
Cholesterol
Diet
Triglycerides
Cell Adhesion Molecules
Interleukin-1
Fibrinogen
ciprofibrate
Hypertriglyceridemia
Hypercholesterolemia
HDL Cholesterol
Therapeutics
Tumor Necrosis Factor-alpha

Keywords

  • Ciprofibrate
  • Combined hyperlipidemia
  • Endothelial function
  • Flow-mediated dilation
  • Inflammatory markers

ASJC Scopus subject areas

  • Physiology
  • Cell Biology

Cite this

The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia. / Kovács, Imre; Toldy, Erzsébet; Ábel, Tatjana; Tarján, Jenö; Császár, A.

In: Endothelium: Journal of Endothelial Cell Research, Vol. 12, No. 4, 07.2005, p. 179-183.

Research output: Contribution to journalArticle

@article{39ff0a2c5b3343dca88d636cb1a54e6e,
title = "The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia",
abstract = "Impairment of flow-mediated dilation (FMD) has been shown to be associated with hypercholesterolemia and hypertriglyceridemia and reduction of cholesterol and/or triglyceride levels can improve FMD. In hyperlipidemia the role of inflammatory substances on endothelial function requires further clarification. In patients with combined hyperlipidemia (n=29), the capacity of FMD was weaker whereas the levels of interleukin (IL)-1α, tumor necrosis factor alpha (TNFα), soluble intercellular adhesion molecule (sICAM), and fibrinogen were higher compared to normolipemic controls with normal FMD adjusted for age and sex. Patients were randomized to a diet-only or to a ciprofibrate treatment group. After 8 weeks FMD levels rose significantly both in the diet-only (10.2{\%}) and the ciprofibrate treatment (79.4{\%}) groups. In the diet-only group improvement of FMD was significantly associated with the reduction of triglyceride (by 15.9{\%}) and cholesterol (6.9{\%}) levels. The much larger improvement of FMD due to ciprofibrate therapy was accompanied by significant reductions of cholesterol (by 14.4{\%}), fibrinogen, IL-1α, and sICAM levels and by significant increase of high-density lipoprotein (HDL) cholesterol concentration, but the change in FMD correlated only with the reduction of the cholesterol level. In line with previous data the authors emphasize that improvement of FMD in patients with combined hyperlipidemia treated with diet and/or ciprofibrate is linked directly to the reduction of cholesterol and triglyceride concentrations rather than to changes in the level of the investigated inflammatory markers.",
keywords = "Ciprofibrate, Combined hyperlipidemia, Endothelial function, Flow-mediated dilation, Inflammatory markers",
author = "Imre Kov{\'a}cs and Erzs{\'e}bet Toldy and Tatjana {\'A}bel and Jen{\"o} Tarj{\'a}n and A. Cs{\'a}sz{\'a}r",
year = "2005",
month = "7",
doi = "10.1080/10623320500227259",
language = "English",
volume = "12",
pages = "179--183",
journal = "Endothelium: Journal of Endothelial Cell Research",
issn = "1062-3329",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia

AU - Kovács, Imre

AU - Toldy, Erzsébet

AU - Ábel, Tatjana

AU - Tarján, Jenö

AU - Császár, A.

PY - 2005/7

Y1 - 2005/7

N2 - Impairment of flow-mediated dilation (FMD) has been shown to be associated with hypercholesterolemia and hypertriglyceridemia and reduction of cholesterol and/or triglyceride levels can improve FMD. In hyperlipidemia the role of inflammatory substances on endothelial function requires further clarification. In patients with combined hyperlipidemia (n=29), the capacity of FMD was weaker whereas the levels of interleukin (IL)-1α, tumor necrosis factor alpha (TNFα), soluble intercellular adhesion molecule (sICAM), and fibrinogen were higher compared to normolipemic controls with normal FMD adjusted for age and sex. Patients were randomized to a diet-only or to a ciprofibrate treatment group. After 8 weeks FMD levels rose significantly both in the diet-only (10.2%) and the ciprofibrate treatment (79.4%) groups. In the diet-only group improvement of FMD was significantly associated with the reduction of triglyceride (by 15.9%) and cholesterol (6.9%) levels. The much larger improvement of FMD due to ciprofibrate therapy was accompanied by significant reductions of cholesterol (by 14.4%), fibrinogen, IL-1α, and sICAM levels and by significant increase of high-density lipoprotein (HDL) cholesterol concentration, but the change in FMD correlated only with the reduction of the cholesterol level. In line with previous data the authors emphasize that improvement of FMD in patients with combined hyperlipidemia treated with diet and/or ciprofibrate is linked directly to the reduction of cholesterol and triglyceride concentrations rather than to changes in the level of the investigated inflammatory markers.

AB - Impairment of flow-mediated dilation (FMD) has been shown to be associated with hypercholesterolemia and hypertriglyceridemia and reduction of cholesterol and/or triglyceride levels can improve FMD. In hyperlipidemia the role of inflammatory substances on endothelial function requires further clarification. In patients with combined hyperlipidemia (n=29), the capacity of FMD was weaker whereas the levels of interleukin (IL)-1α, tumor necrosis factor alpha (TNFα), soluble intercellular adhesion molecule (sICAM), and fibrinogen were higher compared to normolipemic controls with normal FMD adjusted for age and sex. Patients were randomized to a diet-only or to a ciprofibrate treatment group. After 8 weeks FMD levels rose significantly both in the diet-only (10.2%) and the ciprofibrate treatment (79.4%) groups. In the diet-only group improvement of FMD was significantly associated with the reduction of triglyceride (by 15.9%) and cholesterol (6.9%) levels. The much larger improvement of FMD due to ciprofibrate therapy was accompanied by significant reductions of cholesterol (by 14.4%), fibrinogen, IL-1α, and sICAM levels and by significant increase of high-density lipoprotein (HDL) cholesterol concentration, but the change in FMD correlated only with the reduction of the cholesterol level. In line with previous data the authors emphasize that improvement of FMD in patients with combined hyperlipidemia treated with diet and/or ciprofibrate is linked directly to the reduction of cholesterol and triglyceride concentrations rather than to changes in the level of the investigated inflammatory markers.

KW - Ciprofibrate

KW - Combined hyperlipidemia

KW - Endothelial function

KW - Flow-mediated dilation

KW - Inflammatory markers

UR - http://www.scopus.com/inward/record.url?scp=27744452548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744452548&partnerID=8YFLogxK

U2 - 10.1080/10623320500227259

DO - 10.1080/10623320500227259

M3 - Article

VL - 12

SP - 179

EP - 183

JO - Endothelium: Journal of Endothelial Cell Research

JF - Endothelium: Journal of Endothelial Cell Research

SN - 1062-3329

IS - 4

ER -